Drug
Ipatasertib
Ipatasertib: highest development phase Phase 3, developed by Roche. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ipatasertib NCT05862285 | Phase 3 | Cancer |
| Ipatasertib NCT03337724 | Phase 3 | Breast Cancer |
| Ipatasertib NCT04931342 | Phase 2 | Ovarian Cancer |
| Ipatasertib NCT03424005 | Phase 1/2 | Metastatic Breast Cancer |
Latest
No recent events.
Follow Ipatasertib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.